SAN JOSE, Calif. — Theravent Inc. has expanded retail distribution of its Theravent Snore Therapy anti-snoring device to more than 5,000 CVS Pharmacy stores.
The medical device company said this week that Theravent Snore Therapy, also sold at Walgreens drug stores, has reached a milestone: over 5 million nights of snoring treatment since the product’s launch in 2012.
Theravent’s snoring treatment involves small adhesive devices that cover the nostrils. As users breathe in, the device’s patented MicroValve Technology opens, allowing them to breathe in normally. As they breathe out, the MicroValves close to create a gentle pressure that opens the airway and relieves snoring.
According to Theravent, its over-the-counter product uses the same technology found in Provent Therapy, a prescription device for obstructive sleep apnea. The MicroValve Technology is designed to create expiratory positive airway pressure (EPAP) to stop snoring by increasing the pressure inside the airway.
Approximately 50 million Americans are affected by snoring — and that doesn’t include the millions of bed partners disturbed by snorers, the company said.
“Over the years, consumers have been subjected to the perils of gadgets and gimmicks that promise to stop snoring,” stated Theravent chief executive officer Matt Williams. “Theravent stands out from the pack, born from prescription technology, clinically proven and, most importantly, it delivers a quiet night of sleep. Now it’s easier than ever for consumers to access this technology with a national distribution footprint.”
Theravent comes in three versions: Lite for light snorers, Regular for moderate snorers and Max for loud snorers. The Lite and Regular products come in 30- and 90-count boxes, while the Max version comes in a 20-count box. Also available is a trial pack with two of each version.